APUS | tickerfilter.com

Fundamental analysis

39%

Profitability 35%

Dept financing 43%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

9.94%

3 Months

17.50%

6 Months

-5.05%

1 Year

-14.55%

2 Year

-14.55%

Key data

Stock price

$1.88

P/E Ratio

0.00

DAY RANGE

$1.88 - $1.88

EPS

-$0.19

52 WEEK RANGE

$0.95 - $4.03

52 WEEK CHANGE

-$14.55

MARKET CAP

22.385 M

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$31,594

AVERAGE 30 VOLUME

$61,803

Company detail

CEO: Erik C. Emerson
Region: US
Website: www.apimedsus.com
Employees: 2
IPO year: 2025

Issue type:
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. We are located at 2 East Broad Street, 2nd Floor, Hopewell, New Jersey.

APUS - Apimeds Pharmaceuticals US Inc.